BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kyprolis carfilzomib: Phase II data

Researchers at the University of Torino reported data from an open-label, European Phase II trial in 58 patients with newly diagnosed MM showing that IV Kyprolis plus cyclophosphamide and dexamethasone led a 2-year PFS rate of 76% and a 2-year OS rate of 87% at a median follow-up of 18.1 months. Additionally, 77% of patients achieved a very good partial response or better and 64% of patients achieved at least a near complete response after 9 cycles of treatment. Patients received induction therapy every 28 days...

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >